Eisai Clinical Trials

A 30-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of E2020 in Patients with Alzheimer’s Disease.

E2020-A044-304

Study Overview

E2020
donepezil
Not available
Jun 1994 - Jan 1997
Alzheimer's disease
The primary efficacy endpoint was to evaluate the efficacy (primary efficacy parameters included ADAS-cog, CIBI-C Plus, IDDD, QOL, and CDR-SB) of two dose levels of E2020 (donepezil), versus Placebo, in patients with Alzheimer's  Disease.

  • Males and females (age 50 years and over)

  • Completed

  • Phase 3

  • Australia, Canada, Europe, New Zealand, South Africa, United States See more

Results

CSR Synopsis

No download available

Lay Summary

No download available

Publication reference citation

Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller HJ, et al. The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial. Dementia. 1999;10:237-44.

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

Redacted documents are available upon request for this study.

Document type Availability
Protocol
SAP
Sample CRF
Full CSR